PCRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
Pacira BioSciences's adjusted free cash flow per share for the three months ended in Dec. 2023 was $0.665. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $1.07 for the trailing ten years ended in Dec. 2023.
During the past 12 months, Pacira BioSciences's average Cyclically Adjusted FCF Growth Rate was 84.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Pacira BioSciences was 81.10% per year. The lowest was 81.10% per year. And the median was 81.10% per year.
As of today (2024-04-27), Pacira BioSciences's current stock price is $26.33. Pacira BioSciences's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $1.07. Pacira BioSciences's Cyclically Adjusted Price-to-FCF of today is 24.61.
During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Pacira BioSciences was 742.18. The lowest was 23.81. And the median was 62.43.
The historical data trend for Pacira BioSciences's Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | 0.58 | 0.68 | 0.83 | 0.97 | 1.07 |
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted Price-to-FCF falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Pacira BioSciences's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0.665 | / | 129.4194 | * | 129.4194 | |
= | 0.665 |
Current CPI (Dec. 2023) = 129.4194.
Pacira BioSciences Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | -0.253 | 99.695 | -0.328 |
201406 | 0.062 | 100.560 | 0.080 |
201409 | 0.112 | 100.428 | 0.144 |
201412 | 0.164 | 99.070 | 0.214 |
201503 | -0.209 | 99.621 | -0.272 |
201506 | -0.112 | 100.684 | -0.144 |
201509 | -0.165 | 100.392 | -0.213 |
201512 | 0.193 | 99.792 | 0.250 |
201603 | -0.275 | 100.470 | -0.354 |
201606 | -0.036 | 101.688 | -0.046 |
201609 | 0.208 | 101.861 | 0.264 |
201612 | 0.333 | 101.863 | 0.423 |
201703 | -0.095 | 102.862 | -0.120 |
201706 | -0.037 | 103.349 | -0.046 |
201709 | -0.203 | 104.136 | -0.252 |
201712 | 0.292 | 104.011 | 0.363 |
201803 | -0.193 | 105.290 | -0.237 |
201806 | 0.266 | 106.317 | 0.324 |
201809 | 0.297 | 106.507 | 0.361 |
201812 | 0.461 | 105.998 | 0.563 |
201903 | 0.036 | 107.251 | 0.043 |
201906 | 0.489 | 108.070 | 0.586 |
201909 | 0.402 | 108.329 | 0.480 |
201912 | 0.512 | 108.420 | 0.611 |
202003 | -0.012 | 108.902 | -0.014 |
202006 | -0.581 | 108.767 | -0.691 |
202009 | 0.723 | 109.815 | 0.852 |
202012 | 0.721 | 109.897 | 0.849 |
202103 | -0.022 | 111.754 | -0.025 |
202106 | 0.430 | 114.631 | 0.485 |
202109 | 1.038 | 115.734 | 1.161 |
202112 | 0.309 | 117.630 | 0.340 |
202203 | 0.498 | 121.301 | 0.531 |
202206 | 0.344 | 125.017 | 0.356 |
202209 | 0.818 | 125.227 | 0.845 |
202212 | 0.796 | 125.222 | 0.823 |
202303 | 0.273 | 127.348 | 0.277 |
202306 | 0.770 | 128.729 | 0.774 |
202309 | 0.788 | 129.860 | 0.785 |
202312 | 0.665 | 129.419 | 0.665 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.
For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Pacira BioSciences's Cyclically Adjusted Price-to-FCF of today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 26.33 | / | 1.07 | |
= | 24.61 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Pacira BioSciences was 742.18. The lowest was 23.81. And the median was 62.43.
Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.
Thank you for viewing the detailed overview of Pacira BioSciences's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Marcelo Bigal | director | C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609 |
Abraham Ceesay | director | C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830 |
Alethia Young | director | C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080 |
Michael J. Yang | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Roy Winston | officer: Chief Clinical Officer | C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609 |
Lauren Bullaro Riker | officer: Executive Director, Accounting | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054 |
Kristen Marie Williams | officer: CAO and General Counsel | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Mark A. Kronenfeld | director | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054 |
Daryl Gaugler | officer: Chief Operating Officer | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Reinhart Charles A. Iii | officer: Chief Financial Officer | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Ellis Ronald J. Jr. | officer: Chief Strategy Officer | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Max Reinhardt | officer: President | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
David M Stack | director, officer: President and CEO | THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054 |
Dennis Mcloughlin | officer: Chief Commercial Officer | C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
Jonathan Slonin | officer: Chief Clinical Officer | C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054 |
From GuruFocus
By GuruFocus Research • 09-27-2023
By sperokesalga sperokesalga • 03-27-2023
By Stock market mentor Stock market mentor • 01-05-2023
By Marketwired • 10-02-2023
By Marketwired • 09-06-2023
By Marketwired • 07-26-2023
By Marketwired • 08-02-2023
By Marketwired • 10-10-2023
By GuruFocus Research • 11-02-2023
By sperokesalga sperokesalga • 04-26-2023